王刚教授作为项目负责人累计承担市局级以上科研项目24项。 以第一作者和通讯作者发表论文155篇，其中SCI论文84篇，总IF 361.81分，IF>10分5篇。发表核心期刊论文71篇。获国家发明专利/软件著作权8项。作为工作组组长主持编写《中国抑郁障碍防治指南》、《中国抑郁障碍诊疗规范》。作为主编和副主编编写《药物临床试验设计与实施丛书-精神科药物分册》、《精神病学》(第四版)、《精神疾病公共数据元开发》等专著6部。以第一和第二完成人获中华医学一等奖一项、三等奖一项，市级二等奖两项。

代表性论著：

1. Zheng Peng., Yang Jian., Li Yifan., Wu Jing., Liang Weiwei., Yin Bangmin., Tan Xunmin., Huang Yu., Chai Tingjia., Zhang Hanping., Duan Jiajia., Zhou Jingjing., Sun Zuoli., Chen Xu., Marwari Subhi., Lai Jianbo., Huang Tingting., Du Yanli., Zhang Peifen., Perry Seth W., Wong Ma-Li., Licinio Julio., Hu Shaohua., Xie Peng., Wang Gang#.(2020). Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression. Adv Sci (Weinh), 7(7), 1902862. doi:10.1002/advs.201902862. [IF:15.804]

2. Wang Jian., Vila-Rodriguez Fidel., Ge Ruiyang., Gao Sherry., Gregory Elizabeth., Jiang Wei., Yang Chunlin., Wang Gang#.(2020). Accelerated magnetic seizure therapy (aMST) for treatment of major depressive disorder: A pilot study. J Affect Disord, 264(undefined), 215-220. doi:10.1016/j.jad.2019.12.022. [IF: 4.084]

3. Xiao Le., Zhu Xuequan., Gillespie Amy., Feng Yuan., Zhou Jingjing., Chen Xu., Gao Yuanyuan., Wang Xueyi., Ma Xiancang., Gao Chengge., Xie Yunshi., Pan Xiaoping., Bai Yan., Xu Xiufeng., Wang Gang#., Chen Runsen.(2020). v.Effectiveness of mirtazapine as add-on to paroxetine paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial. Psychol Med, undefined(undefined), 1-9. doi:10.1017/S0033291719004069. [IF: 5.641]

4. Feng Yuan., Shi Jianguo., Wang Lili., Zhang Xia., Tan Yunlong., Zhao Jingyuan., Ning Yuping., Xie Shiping., Liu Xuejun., Liu Qi., Li Keqing., Wang Xiaoliang., Li Lehua., Xu Xiufeng., Deng Wei., Luo Xiaoyan., Wang Gang#.(2019). Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. Psychiatry Clin. Neurosci., undefined(undefined), undefined. doi:10.1111/pcn.12965. [ IF:3.489]

5. Hu Y-D., Xiang Y-T., Fang J-X., Zu S., Sha S., Shi H., Ungvari G S., Correll C U., Chiu H F K., Xue Y., Tian T-F., Wu A-S., Ma X., Wang G#.(2016). Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med, 46(3), 623-35. doi:10.1017/S0033291715002159. [IF: 5.641]

6.Guo Tong., Xiang Yu-Tao., Xiao Le., Hu Chang-Qing., Chiu Helen F K., Ungvari Gabor S., Correll Christoph U., Lai Kelly Y C., Feng Lei., Geng Ying., Feng Yuan., Wang Gang#. (2015). Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters. Am J Psychiatry, 172(10), 1004-13. doi:10.1176/appi.ajp.2015.14050652. [IF: 13.655]